Amgen Inc. (AMGN)

In December 2025, Amgen's stock reached a 16-month high but also experienced a 4-week low, closing the month down 3.02% but up 25.58% for the past 12 months. In January 2026, the stock hit a 4-week high. Amgen reported positive results for its obesity drug MariTide and advanced an early-stage obesity candidate. Amgen acquired Dark Blue Therapeutics Ltd. for up to $840 million to bolster its oncology pipeline. Amgen announced an investment exceeding $600 million to establish a new research and development center. Amgen entered into a research collaboration with RO to assess the real-world coverage of GLP-1 medications. Amgen presented at the 44th Annual J.P. Morgan Healthcare Conference in January 2026. Amgen raised its quarterly dividend to $2.52 (annualized $10.08). Amgen reported $5.64 EPS for the quarter, beating the consensus estimate, with revenue of $9.56 billion, up 12.4% year-over-year.

While there is a notable seasonal pattern in Amgen's stock price from June 30 to September 1, this is primarily attributed to investors moving into defensive healthcare stocks during economic concerns rather than direct seasonality in product demand. Healthcare needs are generally prioritized by consumers regardless of broader economic conditions, implying a relatively stable underlying demand for its products.

Amgen Inc. is a multinational biopharmaceutical company headquartered in Thousand Oaks, California, focused on discovering, developing, manufacturing, and delivering innovative medicines within the Biotechnology sector and the Pharmaceuticals and Healthcare industry. Amgen's therapeutic areas of focus include cancer, heart disease, osteoporosis, inflammatory diseases, and rare diseases. Amgen's major products include Prolia and XGEVA for bone diseases, Enbrel for autoimmune diseases, Repatha for hyperlipidemia, Otezla for psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, Aranesp to stimulate erythropoiesis, Blincyto for acute lymphoblastic leukemia, Neulasta for neutropenia, Epogen for anemia, Aimovig for migraine headaches, Mvasi and Kanjinti as oncology biosimilars, Parsabiv for hyperparathyroidism, Vectibix, Amjevita, Sensipar/Mimpara, Neupogen, Imlygic, Corlanor, Avsola, Lumakras targeting KRAS mutations in cancers, Tavneos for rare diseases, and Imdelltra.

Amgen operates globally, with its headquarters in Thousand Oaks, California, US. The company's operations are divided into two main regions: the United States and the Rest of the World (ROW). Amgen has manufacturing facilities in the US, Puerto Rico, Ireland, the Netherlands, and Singapore. The company has a presence in numerous countries across Asia Pacific, the Americas, Europe, the Middle East, and Africa, including Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Denmark, Egypt, Finland, France, Germany, Greece, Hungary, India, Italy, Japan, Korea, Mexico, Norway, Poland, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Arab Emirates, and the United Kingdom.

Amgen has maintained a strong brand reputation, being named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes in 2024. The acquisition of Dark Blue Therapeutics strengthens its oncology pipeline, contributing positively to its reputation. Positive clinical trial results for MariTide have enhanced its reputation for pipeline development. Amgen's commitment to science education, community involvement, access to medicines, and ethical and environmental responsibility supports its positive brand image.

Amgen Inc. is largely controlled by institutional shareholders, who collectively own approximately 78% of the company. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., State Street Corp, Capital International Investors, Capital World Investors, Charles Schwab Investment Management Inc, Geode Capital Management, Llc, Invesco Capital Management (QQQ Trust), PRIMECAP Management Company, Morgan Stanley Smith Barney, and Wells Fargo Advisors. Individual insider ownership is under 1%. Recent insider trades include officers selling shares in November 2025.